[Serratia marcescens vaccine in the treatment of malignant pleural effusion].
OBJECTIVE
To evaluate the efficacy and toxicity of Serratia marcescens (S311) vaccine in the treatment of malignant pleural effusion.


METHODS
Thirty-four patients with malignant pleural effusion were given S311 as intrapleural injection with a dose of 10(9) U (0.32 mg) on D 1, 8 and 15, and observed for four weeks.


RESULTS
The overall response rate (CR + PR) was 97.1% (CR in 12 patients and PR in 21 patients). The systemic toxicity was mild, including fever (82.4%), pleuritic pain (50.7%), nansea (26.5%), dyspnea (17.5%) and chills (5.9%).


CONCLUSIONS
Serratia marcescens vaccine is effective for malignant pleural effusion, with tolerable toxic effects. Further study is warranted.
Shi
Heling
H
Beijing Thoracic Tumour and Tuberculosis Hospital, Beijing 101149, China.
Zhu
Yunzhong
Y
Xu
Liyan
L
Liu
Zhe
Z
You
Yonghong
Y
Meng
Qiyi
Q
Zhang
Xinyong
X
Xu
Juntao
J
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001428:Bacterial Vaccines / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D002637:Chest Pain / Q000139:chemically induced; D004305:Dose-Response Relationship, Drug; D005260:Female; D005334:Fever / Q000139:chemically induced; D006801:Humans; D008297:Male; D008875:Middle Aged; D010996:Pleural Effusion / Q000188:drug therapy* / Q000276:immunology; D012706:Serratia marcescens / Q000276:immunology*; D013997:Time Factors; D016896:Treatment Outcome
D001428:Bacterial Vaccines